Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Alzheimer's Disease: Current Status and Future Prospects
share announcement

Alzheimer's Disease: Current Status and Future Prospects

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 11039

Special Issue Editors

Dr. Sireesha Manne

E-Mail Website
Guest Editor
Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
Interests: neurodegeneration; biomarker; tau; amyloid-beta
Dr. Naveen Kondru

E-Mail Website
Guest Editor
Mayo Clinic, Jacksonville, FL 32224, USA
Interests: infectious diseases of nervous system; prions; stem cells; organoids; proteomics; genetics; RNAs; veterinary medicine & One Health

Special Issue Information

Dear Colleagues,

This special Edition “Alzheimer’s disease: Current State and Future Prospects will mainly focus on the Alzheimer’s disease (AD) and its potential disease-modifying diagnostics and therapeutics that are currently being studied and advances that can be proved beneficial for patients with AD. AD is one of the major neurodegenerative disease-causing dementias and causes significant burden both physically and mentally in elderly population and their caregivers. AD is characterized by either extra cellular accumulation of amyloid beta in the form of amyloid plaques or intracellular accumulation of tau in the form of neurofibrillary tangles. Despite of several efforts to find effective ways to prevent or slowing down of disease progression, AD remains as a disease without cure. Hence the current edition mainly focuses on the diagnostic biomarkers such as tau, amyloid beta or other circulating proteins that helps in the earlier diagnosis and thereby preventing its progression.

We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.

Dr. Sireesha Manne
Dr. Naveen Kondru
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Alzheimer’s disease
  • tau
  • biomarker
  • diagnosis
  • APOE
  • amyloid beta
  • slow progression
  • fast progression

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

14 pages, 684 KiB  
Review
NF-κB Pathway and Its Inhibitors: A Promising Frontier in the Management of Alzheimer’s Disease
by Bhagavathi Sundaram Sivamaruthi, Neha Raghani, Mehul Chorawala, Sankha Bhattacharya, Bhupendra G. Prajapati, Gehan M. Elossaily and Chaiyavat Chaiyasut
Biomedicines 2023, 11(9), 2587; https://doi.org/10.3390/biomedicines11092587 - 21 Sep 2023
Cited by 18 | Viewed by 5421
Abstract
The nuclear factor kappa B (NF-κB) pathway has emerged as a pivotal player in the pathogenesis of various diseases, including neurodegenerative illnesses like Alzheimer’s disease (AD). The involvement of the NF-κB pathway in immune system responses, inflammation, oxidative stress, and neuronal survival highlights [...] Read more.
The nuclear factor kappa B (NF-κB) pathway has emerged as a pivotal player in the pathogenesis of various diseases, including neurodegenerative illnesses like Alzheimer’s disease (AD). The involvement of the NF-κB pathway in immune system responses, inflammation, oxidative stress, and neuronal survival highlights its significance in AD progression. We discuss the advantages of NF-κB pathway inhibition, including the potential to mitigate neuroinflammation, modulate amyloid beta (Aβ) production, and promote neuronal survival. However, we also acknowledge the limitations and challenges associated with this approach. Balancing the fine line between dampening inflammation and preserving physiological immune responses is critical to avoid unintended consequences. This review combines current knowledge on the NF-κB pathway’s intricate involvement in AD pathogenesis, emphasizing its potential as a therapeutic target. By evaluating both advantages and limitations, we provide a holistic view of the feasibility and challenges of NF-κB pathway modulation in AD treatment. As the quest for effective AD therapies continues, an in-depth understanding of the NF-κB pathway’s multifaceted roles will guide the development of targeted interventions with the potential to improve AD management. Full article
(This article belongs to the Special Issue Alzheimer's Disease: Current Status and Future Prospects)
►▼ Show Figures

Figure 1

15 pages, 4204 KiB  
Review
Ultra-Early Screening of Cognitive Decline Due to Alzheimer’s Pathology
by Pengxu Wei
Biomedicines 2023, 11(5), 1423; https://doi.org/10.3390/biomedicines11051423 - 11 May 2023
Cited by 1 | Viewed by 5075
Abstract
Alzheimer’s pathology can be assessed and defined via Aβ and tau biomarkers. The preclinical period of Alzheimer’s disease is long and lasts several decades. Although effective therapies to block pathological processes of Alzheimer’s disease are still lacking, downward trends in the incidence and [...] Read more.
Alzheimer’s pathology can be assessed and defined via Aβ and tau biomarkers. The preclinical period of Alzheimer’s disease is long and lasts several decades. Although effective therapies to block pathological processes of Alzheimer’s disease are still lacking, downward trends in the incidence and prevalence of dementia have occurred in developed countries. Accumulating findings support that education, cognitive training, physical exercise/activities, and a healthy lifestyle can protect cognitive function and promote healthy aging. Many studies focus on detecting mild cognitive impairment (MCI) and take a variety of interventions in this stage to protect cognitive function. However, when Alzheimer’s pathology advances to the stage of MCI, interventions may not be successful in blocking the development of the pathological process. MCI individuals reverting to normal cognitive function exhibited a high probability to progress to dementia. Therefore, it is necessary to take effective measures before the MCI stage. Compared with MCI, an earlier stage, transitional cognitive decline, may be a better time window in which effective interventions are adopted for at-risk individuals. Detecting this stage in large populations relies on rapid screening of cognitive function; given that many cognitive tests focus on MCI detection, new tools need to be developed. Full article
(This article belongs to the Special Issue Alzheimer's Disease: Current Status and Future Prospects)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop